drugset / Trial / NCT06566248
A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B
RandomizedParallel-groupSingle-blindTreatment
Summary
To evaluate the efficacy and safety of combined/uncombined nucleoside (acid) analogues of TQA3810 tablets.
Timeline
- Start
- 2024-03-20
- Primary completion
- 2024-09
- Completion
- 2025-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQA3810 | Small molecule | 0.1 mg | Oral |
| Subject | TQA3810 | Small molecule | 0.2 mg | Oral |
| Subject | TQA3810 | Small molecule | 0.3 mg | Oral |
| Comparator | Entecavir | Small molecule | — | Oral |
| Comparator | Tenofovir disoproxil fumarate | Small molecule | — | Oral |
| Comparator | tenofovir alafenamide | Small molecule | — | Oral |